Tag Archives: diabetic macular edema

November, 2017

27 November
Regeneron Drops Eylea Combination After Phase 2 Failures

TARRYTOWN, N.Y., Nov. 27, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from two Phase 2 studies that added the angiopoietin2 (Ang2) antibody nesvacumab to EYLEA® (aflibercept) Injection did not provide sufficient differentiation to warrant Phase 3 development. The RUBY study evaluated patients with diabetic macular edema (DME) and the ONYX study …
Share

15 June
Roche to License Eleven Bio’s IL-6 Antagonist Antibody Technology in $270 Million Deal

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it has entered into an exclusive license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) relating to Eleven’s Interleukin-6 (IL-6) technology. Under the terms of …
Share

25 March
Bayer and Regeneron Partner to Develop Novel Combination Therapy for Eye Diseases

TARRYTOWN, N.Y., March 24, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer will jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and the vascular endothelial growth factor (VEGF) trap aflibercept, for the treatment of serious eye diseases. Two separate Phase 2 clinical studies are evaluating …
Share

25 March
FDA Expands Approval of Regeneron’s Eylea for Diabetic Retinopathy in Patients with Diabetic Macular Edema

The US Food and Drug Administration (FDA) has expanded approval of Regeneron’s macular degeneration drug for treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The agency’s approval of Regeneron Pharmaceuticals’ Eylea (afilibercept) injection for treatment of diabetic retinopathy (DR) in patients with DME marks the fourth approval …
Share

9 February
FDA Approves Genentech’s Lucentis for Treatment of Diabetic Retinopathy

Genentech’s Lucentis (ranibizumab injection) received expanded US approval for treatment of diabetic retinopathy (DR) in patients with diabetic macular edema (DME). The company announced that the drug received its fourth indication approved by the US Food and Drug Administration (FDA). The agency approved Lucentis 0.3 mg to be used along …
Share